{
    "name": "tirzepatide",
    "comment": "Rx",
    "other_names": [
        "Mounjaro"
    ],
    "classes": [
        "Antidiabetics",
        "Glucagon-like Peptide-1 Agonists",
        "Antidiabetics",
        "Glucose-dependent Insulinotropic Polypeptides"
    ],
    "source": "https://reference.medscape.com/drug/mounjaro-tirzepatide-4000264",
    "pregnancy": {
        "common": [
            "Data are insufficient regarding use in pregnant females to evaluate for a drug-associated risk of major birth defects, miscarriage, or other adverse maternal or fetal outcomes",
            "On the basis of animal reproduction studies, there may be risks to the fetus from tirzepatide exposure during pregnancy",
            "Use during pregnancy only if potential benefit justifies the potential risk to the fetus"
        ],
        "specific": [
            {
                "type": "Clinical considerations ",
                "description": [
                    "Poorly controlled diabetes in pregnancy increases maternal risk for diabetic ketoacidosis, preeclampsia, spontaneous abortions, preterm delivery, and delivery complications",
                    "Poorly controlled diabetes increases fetal risk for major birth defects, stillbirth, and macrosomia-related morbidity"
                ]
            },
            {
                "type": "Contraception ",
                "description": [
                    "Tirzepatide may reduce efficacy of oral hormonal contraceptives owing to delayed gastric emptying",
                    "This delay is largest after the first dose and diminishes over time",
                    "Advise patients using oral hormonal contraceptives to switch to a non-oral contraceptive method or to add a barrier method of contraception for 4 weeks after initiation and for 4 weeks after each dose escalation"
                ]
            },
            {
                "type": "Animal studies ",
                "description": [
                    "In pregnant rats administered tirzepatide during organogenesis, fetal growth reductions and fetal abnormalities occurred at clinical exposure based on AUC",
                    "In rabbits administered tirzepatide during organogenesis, fetal growth reductions were observed at clinically relevant exposures based on AUC"
                ]
            }
        ]
    },
    "lactation": {
        "common": []
    },
    "warnings": {
        "black_box_warning": {
            "common": [],
            "specific": [
                {
                    "type": "Risk of thyroid C-cell tumors",
                    "description": [
                        "In rodents, tirzepatide causes dose-dependent and treatment-duration-dependent thyroid C-cell tumors at clinically relevant exposures; unknown whether tirzepatide causes thyroid C-cell tumors, including medullary thyroid carcinoma (MTC), in humans; human relevance of tirzepatide-induced rodent thyroid C-cell tumors has not been determined",
                        "Contraindicated in patients with a personal or family history of MTC or in patients with multiple endocrine neoplasia syndrome type 2",
                        "Advise patients of potential risk for MTC and possible symptoms of thyroid tumors (eg, a mass in the neck, dysphagia, dyspnea, persistent hoarseness)",
                        "Routine monitoring of serum calcitonin or use of thyroid ultrasound is of uncertain value for early detection of MTC"
                    ]
                }
            ]
        },
        "contraindicators": {
            "common": [
                "Personal or family history of MTC or in patients with multiple endocrine neoplasia syndrome type 2",
                "Known hypersensitivity to tirzepatide or to any of the product components"
            ],
            "specific": []
        },
        "cautions": {
            "common": [
                "On the basis of findings in rats and mice, may cause thyroid C-cell tumors, including MTC, in humans; human relevance of tirzepatide-induced rodent thyroid C-cell tumors has not been determined",
                "Acute pancreatitis, including fatal and non-fatal hemorrhagic or necrotizing pancreatitis, observed in patients treated with GLP-1 receptor agonists; after initiating, monitor for signs and symptoms of pancreatitis (eg, persistent severe abdominal pain, which sometimes radiates to the back and may or may not be accompanied by vomiting); if pancreatitis suspected, discontinue and do not restart if confirmed",
                "Rapid improvement in glucose control associated with temporary worsening of diabetic retinopathy; tirzepatide has not been studied in patients with nonproliferative diabetic retinopathy requiring acute therapy, proliferative diabetic retinopathy, or diabetic macular edema; monitor patients with a history of diabetic retinopathy ",
                "Gastrointestinal (GI) adverse reactions, sometimes severe, reported; has not been studied in patients with severe GI disease, including severe gastroparesis, and is not recommended in these patients",
                "Acute gallbladder disease (eg, cholelithiasis, cholecystitis) reported in GLP-1 receptor agonist trials and postmarketing surveillance; if suspected, gallbladder studies and appropriate clinical follow-up are indicated"
            ],
            "specific": [
                {
                    "type": "Kidney injury",
                    "description": [
                        "Acute kidney injury and worsening of chronic renal failure, which may sometimes require hemodialysis in patients treated with GLP-1 receptor agonists, has been described",
                        "Most reported events occurred in patients who had experienced nausea, vomiting, diarrhea, or dehydration",
                        "Events also reported in patients without known underlying renal disease",
                        "Monitor renal function when initiating or escalating doses in patients reporting severe adverse GI reactions "
                    ]
                },
                {
                    "type": "Hypersensitivity",
                    "description": [
                        "Serious hypersensitivity reactions reported with GLP-1 receptor agonists; caution in patients with history of angioedema or anaphylaxis with a GLP-1 receptor agonist",
                        "Unknown whether such patients will be predisposed to these reactions with tirzepatide  ",
                        "If hypersensitivity reactions occur, discontinue treatment, treat promptly, and monitor until signs and symptoms resolve"
                    ]
                },
                {
                    "type": "Drug interaction overview ",
                    "description": [
                        "Insulin secretagogues or insulin",
                        "May require dosage modification",
                        "Coadministration with insulin secretagogues (eg, sulfonylureas) or insulin may increase risk of hypoglycemia",
                        "Consider lower dose of secretagogue or insulin to reduce risk of hypoglycemia",
                        "Inform patients using concomitant medications of risk of hypoglycemia and educate them on signs and symptoms of hypoglycemia",
                        "Oral drugs with narrow therapeutic index ",
                        "Caution/dosage modification",
                        "Tirzepatide may delay gastric emptying, thereby potentially impacting oral absorption",
                        "Caution with drugs having a narrow therapeutic index (eg, warfarin)",
                        "Advise patients using oral hormonal contraceptives to switch to a non-oral contraceptive method, or to add a barrier method of contraception for 4 weeks after initiation and for 4 weeks after each tirzepatide dose escalation "
                    ]
                }
            ]
        }
    },
    "interactions": [
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "lonapegsomatropin",
            "description": {
                "common": "lonapegsomatropin decreases effects of tirzepatide by Other (see comment). Use Caution/Monitor. \nComment: Closely monitor blood glucose when treated with antidiabetic agents. Lonapegsomatropin may decrease insulin sensitivity, particularly at higher doses. Patients with diabetes mellitus may require adjustment of their doses of insulin and/or other antihyperglycemic agents."
            }
        }
    ],
    "adverse effects": [
        {
            "name": "Blood glucose",
            "percent": "54"
        },
        {
            "name": "mg",
            "percent": "14-19"
        },
        {
            "name": "dL",
            "percent": "12-18"
        },
        {
            "name": "added to basal insulin",
            "percent": "12-17"
        },
        {
            "name": "Nausea",
            "percent": "5-11"
        },
        {
            "name": "Diarrhea",
            "percent": "5-9"
        },
        {
            "name": "Decreased appetite",
            "percent": "5-8"
        },
        {
            "name": "Vomiting",
            "percent": "5-7"
        },
        {
            "name": "Dyspepsia",
            "percent": "5-6"
        },
        {
            "name": "Constipation",
            "percent": "3.2"
        },
        {
            "name": "Abdominal pain",
            "percent": "3.2"
        },
        {
            "name": "Injection site reactions",
            "percent": "1-2"
        },
        {
            "name": "Hypersensitivity reactions",
            "percent": "0.5"
        },
        {
            "name": "Severe hypoglycemia",
            "percent": null
        },
        {
            "name": "add",
            "percent": null
        },
        {
            "name": "on to basal insulin",
            "percent": null
        },
        {
            "name": "Acute gallbladder disease",
            "percent": null
        }
    ]
}